Response of leptomeningeal metastases from breast cancer to hormonal therapy

Neurology. 2000 Jul 12;55(1):117-9. doi: 10.1212/wnl.55.1.117.

Abstract

Intraventricular chemotherapy with radiotherapy is the standard treatment of leptomeningeal metastasis (LM) from breast cancer; this treatment increases median survival only to about 3 months and is frequently complicated by serious side effects. The authors describe two patients with LM from breast cancer who were treated with hormonal therapy, which provided a neurologic response of at least 12 months and a survival of 14+ and 19 months. Hormonal therapy can be effective and nontoxic for patients with LM from breast cancer.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / therapy
  • Carcinoma, Lobular / drug therapy*
  • Carcinoma, Lobular / secondary*
  • Fatal Outcome
  • Female
  • Humans
  • Meningeal Neoplasms / drug therapy*
  • Meningeal Neoplasms / pathology
  • Meningeal Neoplasms / secondary*
  • Middle Aged
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal